stockrow
Saturday 7 November 2026
Export VOGX’s income statement to Excel — free account
Vogenx Inc
VOGX Healthcare Biotechnology
17.45
0.78
−4.28%
Follow VOGX
Alert me
| Jun '26 | Dec '25 | Jun '25 | |
|---|---|---|---|
Current Ratio |
0.44 | 0.43 | — |
Net Debt/EBITDA |
0.54 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | — |
Debt/Equity |
0.00 | 0.00 | — |
Operating CF/Net income |
0.00 | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
0.00 | — | 0.00 |
Cash per Share |
0.04 | 0.00 | 0.00 |
Shareholders Equity per Share |
(0.33) | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | — | 0.00 |
Book value per Share |
(0.33) | 0.00 | 0.00 |
| Other line items | |||
Quick Ratio |
0.06 | 0.38 | — |
Revenue per Share |
0.00 | — | 0.00 |
Operating CF per Share |
0.00 | — | 0.00 |
Capex per Share |
0.00 | — | 0.00 |
Working Capital |
(1.78) | (0.92) | — |
Net Current Asset Value |
(1.78) | (0.92) | — |
Columns are period end dates · fundamentals updated 2 Nov 2026